Headquartered in Canonsburg, PA Fiscal year ends December NASDAQ: VTRS viatris.com
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose portfolio spans generics, value-added medicines, established brands and innovative medicines.
- **Reporting segments:** Developed Markets, Greater China, JANZ (Japan, Australia and New Zealand) and Emerging Markets.
- **Sales mix:** Net sales are split between Brands and Generics, with Brands the larger category.
- **Key global brands:** Lipitor, Norvasc, EpiPen Auto-Injectors, Lyrica, Creon, Viagra, Zoloft, Celebrex, Effexor and the Xalatan family (Xalabrands). Segment products include Influvac, Yupelri, Xanax, Amitiza and Dymista.
- **Innovative medicines push:** Viatris is building this business through launches and approvals such as Gwyn Lo (contraceptive patch), RYZUMVI (presbyopia and mydriasis) and WAKIX (approved in Japan). It also has fast-acting meloxicam pending approval and a planned acquisition of non-opioid pain therapy company Pacira BioSciences.
- **Restructuring and footprint:** The company is executing an enterprise-wide strategic review and restructuring program. It operates global centers in Pittsburgh, Shanghai and Hyderabad, India, and runs a global manufacturing network that includes the Nashik, India oral solid dose facility, currently under remediation. Updated
A fifth straight earnings beat came with a shutdown attached: the FDA's Official Action Indicated classification at the Nashik, India plant cost roughly $100 million of quarterly revenue. Management still raised the midpoints of every 2026 guidance metric.
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash,…
Monday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Accenture, Clorox, Fiserv, Moderna, Planet Fitness, Sarepta Therapeutics, Tesla, Under Armour, Ventas, Viatris, Wayfair and Welltower.
Friday's top analyst upgrades and downgrades included Activision Blizzard, Altria, AppLovin, Bumble, Cano Health, Hanesbrands, Okta, Palo Alto Networks, Redfin, RingCentral, Rivian Automotive, Roblox, Salesforce, SunPower, TJX Companies, Upstart and Viatris.
Wednesday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Eli Lilly, Home Depot, Medtronic, Palantir Technologies, Snowflake, Take-Two Interactive Software, Viatris and Walgreens Boots Alliance.
Before U.S. markets open Monday morning, these four companies will be reporting quarterly earnings.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose portfolio spans generics, value-added medicines, established brands and innovative medicines. - **Reporting segments:** Developed Markets, Greater China, JANZ (Japan, Australia and New Zealand) and Emerging Markets. - **Sales mix:** Net sales are split…
24/7 Wall St.'s 12-month price target for VTRS is $23.73, rated Buy. The Wall Street consensus target is $20.00. VTRS price prediction →
